Medulloblastomas in Pediatric and Adults

Area of Science:

• Neuro-oncology
• Pediatric oncology
• Neurosurgery

Background:

• Medulloblastoma is the most common malignant pediatric brain tumor, originating in the cerebellum.
• It accounts for up to 25% of childhood central nervous system (CNS) tumors.
• While highly malignant, significant progress has been made in understanding its oncogenesis and treatment.

Purpose of the Study:

• To review the current understanding and treatment of medulloblastoma.
• To highlight advancements in surgical techniques and adjuvant therapies.
• To identify challenges in long-term quality of life and future research directions.

Main Methods:

• Surgical resection aims for maximal tumor removal with minimal neurological deficit.
• Advanced surgical tools (microscope, ultrasound suction) and improved intensive care have reduced mortality.
• Radiotherapy is the primary treatment for patients over 3 years old, often combined with chemotherapy.

Main Results:

• Surgical mortality is less than 1%, with 5-10% experiencing neurological complications.
• Radiotherapy significantly improves recurrence-free survival.
• Current treatments can cure 80% of patients, but long-term quality of life is often impaired.

Conclusions:

• Optimizing medulloblastoma treatment requires balancing efficacy with reduced long-term side effects.
• Reducing radiation doses to the CNS is a key goal.
• Molecular genetic research is crucial for developing new, improved treatment protocols and enhancing patient quality of life.